About Vericel Corporation
https://vcel.comVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
CEO
Dominick C. Colangelo
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-10-16 | Reverse | 1:20 |
| 2010-02-18 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 3 of 153
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Truist Securities
Buy
Canaccord Genuity
Buy
HC Wainwright & Co.
Buy
Stephens & Co.
Overweight
BTIG
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.06M
Value:$300.76M
BLACKROCK, INC.
Shares:7.57M
Value:$282.56M
VANGUARD GROUP INC
Shares:3.52M
Value:$131.24M
Summary
Showing Top 3 of 305
About Vericel Corporation
https://vcel.comVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $67.5M ▲ | $46.13M ▼ | $5.07M ▲ | 7.52% ▲ | $0.1 ▲ | $8.18M ▲ |
| Q2-2025 | $63.24M ▲ | $48.64M ▼ | $-553K ▲ | -0.87% ▲ | $-0.01 ▲ | $2.43M ▲ |
| Q1-2025 | $52.6M ▼ | $49.06M ▲ | $-11.25M ▼ | -21.38% ▼ | $-0.23 ▼ | $-8.41M ▼ |
| Q4-2024 | $75.38M ▲ | $40.02M ▼ | $19.81M ▲ | 26.28% ▲ | $0.4 ▲ | $21.59M ▲ |
| Q3-2024 | $57.91M | $44.12M | $-901K | -1.56% | $-0.02 | $579K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $135.38M ▲ | $453.27M ▲ | $131.42M ▲ | $321.86M ▲ |
| Q2-2025 | $116.88M ▲ | $435.61M ▲ | $128.8M ▼ | $306.81M ▲ |
| Q1-2025 | $112.9M ▼ | $424.59M ▼ | $129.1M ▼ | $295.49M ▲ |
| Q4-2024 | $116.21M ▲ | $432.72M ▲ | $140.75M ▲ | $291.97M ▲ |
| Q3-2024 | $101.73M | $390.4M | $132.93M | $257.47M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $5.07M ▲ | $22.08M ▲ | $-3.38M ▲ | $1.17M ▼ | $19.87M ▲ | $19.45M ▼ |
| Q2-2025 | $-553K ▲ | $8.21M ▲ | $-9.03M ▲ | $1.64M ▼ | $827K ▲ | $22.43M ▲ |
| Q1-2025 | $-11.25M ▼ | $6.6M ▼ | $-15.14M ▼ | $3.2M ▼ | $-5.34M ▼ | $-7.61M ▼ |
| Q4-2024 | $19.81M ▲ | $22.24M ▲ | $-14.65M ▲ | $7.11M ▲ | $14.7M ▲ | $8.46M ▼ |
| Q3-2024 | $-901K | $10.18M | $-21.21M | $5.52M | $-5.5M | $40.96M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 MACI Implants And Kits | $70.00M ▲ | $50.00M ▼ | $50.00M ▲ | $60.00M ▲ |
CEO
Dominick C. Colangelo
Compensation Summary
(Year 2019)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-10-16 | Reverse | 1:20 |
| 2010-02-18 | Reverse | 1:8 |
ETFs Holding This Stock
Summary
Showing Top 3 of 153
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Truist Securities
Buy
Canaccord Genuity
Buy
HC Wainwright & Co.
Buy
Stephens & Co.
Overweight
BTIG
Neutral
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.06M
Value:$300.76M
BLACKROCK, INC.
Shares:7.57M
Value:$282.56M
VANGUARD GROUP INC
Shares:3.52M
Value:$131.24M
Summary
Showing Top 3 of 305